Journal of Clinical Endocrinology & Metabolism, Vol 76, 950-955, Copyright © 1993 by Endocrine Society

ARTICLES

Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins

JP Miell, AM Taylor, M Zini, HG Maheshwari, RJ Ross and R Valcavi
Department of Medicine, King's College School of Medicine, London, United Kingdom.

Normal thyroid status is a prerequisite for the normal growth and development of many tissues. The interrelationships between the thyroid and pituitary-GH-insulin-like growth factor (IGF) axes are complex and not yet fully understood. We have studied the effects of hypothyroidism (n = 22) and hyperthyroidism (n = 17) on levels of serum immunoreactive IGF-I and II, IGF-binding proteins (IGFBP-1 and -3), and IGF bioactivity before and during treatment. We have also assessed changes in GH-binding activity (GHBP). Mean immunoreactive (IR) IGF-I levels in the hypothyroid group rose from 106.6 +/- 10.6 micrograms/L at diagnosis to 139.9 +/- 12.7 micrograms/L (P = 0.009) on normalization of thyroid function. In hyperthyroidism, mean IGF-I levels (258.9 +/- 33.9 micrograms/L) were high initially and fell to 188.7 +/- 14.8 micrograms/L (P = 0.04) after treatment. IR IGF-I levels correlated positively with free T3 and free T4 and negatively with TSH levels. Mean serum IGF-II levels were low in hypothyroid patients (375.2 +/- 37.3) and rose during treatment (516.9 +/- 59.4 micrograms/L; P = 0.04). In the hyperthyroid subjects, however, there was no significant change during therapy (625.0 +/- 66.9 vs. 621.9 +/- 120.8 micrograms/L; P = 0.98). IGF bioactivity potency ratios were low in the hypothyroid group (0.26 +/- 0.03 U/mL) and rose to 0.71 +/- 0.10 U/mL (P = 0.01) during treatment. IGF bioactivity in the hyperthyroid group was also low (0.38 +/- 0.05 U/mL) and rose significantly during treatment (0.81 +/- 0.06 U/mL; P = 0.003). Mean IGFBP-1 levels (29.8 +/- 5.7 micrograms/L) were unaltered by treatment of hypothyroid subjects (28.4 +/- 4.8 micrograms/L). In contrast, IGFBP-1 levels in the hyperthyroid subjects were high at diagnosis (134.6 +/- 26.6 micrograms/L) and fell significantly (71.3 +/- 14.3 micrograms/L; P = 0.04) during treatment. In the hypothyroid group, IGFBP-3 levels rose from an initial mean of 1.98 +/- 0.17 to 2.67 +/- 0.27 mg/L (P = 0.04) during treatment. The higher mean pretreatment levels in the thyrotoxic group (3.46 +/- 0.32 mg/L) were unaltered by treatment (3.20 +/- 0.51 mg/L; P = 0.71). GHBP was low in the hypothyroid group at diagnosis (28.5 +/- 2.5%) and rose during treatment to 40.6 +/- 3.9% (P = 0.02). We have confirmed that IR IGF-I levels are low in hypothyroidism and have demonstrated a reduction in IGF bioactivity and IGF-II and IGFBP-3 levels, and low GH- binding activity, which may reflect a reduction in the processing of GH receptors.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				M. B. Zimmermann, P. L. Jooste, N. S. Mabapa, X. Mbhenyane, S. Schoeman, R. Biebinger, N. Chaouki, M. Bozo, L. Grimci, and J. Bridson Treatment of Iodine Deficiency in School-Age Children Increases Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein-3 Concentrations and Improves Somatic Growth J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 437 - 442. [Abstract] [Full Text] [PDF]

				Y. Debaveye, B. Ellger, L. Mebis, E. Van Herck, W. Coopmans, V. Darras, and G. Van den Berghe Tissue Deiodinase Activity during Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination with Growth Hormone-Releasing Peptide-2 Endocrinology, December 1, 2005; 146(12): 5604 - 5611. [Abstract] [Full Text] [PDF]

				R. P. Peeters, A. W. van den Beld, H. van Toor, A. G. Uitterlinden, J. A. M. J. L. Janssen, S. W. J. Lamberts, and T. J. Visser A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 256 - 263. [Abstract] [Full Text] [PDF]

				C. Schmid, M. Brandle, C. Zwimpfer, J. Zapf, and P. Wiesli Effect of Thyroxine Replacement on Creatinine, Insulin-Like Growth Factor 1, Acid-Labile Subunit, and Vascular Endothelial Growth Factor Clin. Chem., January 1, 2004; 50(1): 228 - 231. [Full Text] [PDF]

				R. P. A. Rooman, G. Kuijpers, R. Gresnigt, R. Bloemen, J. G. Koster, and S. C. van Buul-Offers Dexamethasone Differentially Inhibits Thyroxine- or Growth Hormone-Induced Body and Organ Growth of Snell Dwarf Mice Endocrinology, June 1, 2003; 144(6): 2553 - 2558. [Abstract] [Full Text] [PDF]

				K. B. Markou, P. Paraskevopoulou, K. S. Karaiskos, M. Makri, N. A. Georgopoulos, G. Iconomou, C. Mengreli, and A. G. Vagenakis Hyperthyrotropinemia during Iodide Administration in Normal Children and in Children Born with Neonatal Transient Hypothyroidism J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 617 - 621. [Abstract] [Full Text] [PDF]

				D. R. Clemmons Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships Endocr. Rev., December 1, 2001; 22(6): 800 - 817. [Abstract] [Full Text] [PDF]

				H. C. Freake, K. E. Govoni, K. Guda, C. Huang, and S. A. Zinn Actions and Interactions of Thyroid Hormone and Zinc Status in Growing Rats J. Nutr., April 1, 2001; 131(4): 1135 - 1141. [Abstract] [Full Text]

				H. Pantazi and P. D. Papapetrou Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1099 - 1106. [Abstract] [Full Text]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				S. Ramos, L. Goya, C. Alvarez, and A. M. Pascual-Leone Mechanism of Hypothyroidism Action on Insulin-Like Growth Factor-I and -II from Neonatal to Adult Rats: Insulin Mediates Thyroid Hormone Effects in the Neonatal Period Endocrinology, December 1, 1998; 139(12): 4782 - 4792. [Abstract] [Full Text] [PDF]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				B. Boersma and J. M. Wit Catch-up Growth Endocr. Rev., October 1, 1997; 18(5): 646 - 661. [Abstract] [Full Text]

				G. A. Brent The Molecular Basis of Thyroid Hormone Action N. Engl. J. Med., September 29, 1994; 331(13): 847 - 853. [Full Text]